FN2 Earnings Intelligence
Alnylam Pharmaceuticals, Inc. income statement
Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $820 | $866.4 | $812.7 | $966.4 | $1,657.2 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $844.3 | $1,037.4 | $1,828.3 | $2,248.2 | $3,713.9 | $5,467.5 | $6,912.2 |
| % Growth | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% | 47.2% | 26.4% |
| Gross Profit | $729.3 | $897.2 | $1,560.1 | $1,941.7 | $3,036.8 | - | - |
| % Margin | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% | - | - |
| EBITDA | -$671.9 | -$746 | -$230.6 | -$121.8 | $556.4 | - | - |
| % Margin | -79.6% | -71.9% | -12.6% | -5.4% | 15.0% | - | - |
| Net Income | -$852.8 | -$1,131.2 | -$440.2 | -$278.2 | $313.7 | - | - |
| % Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% | - | - |
| Diluted EPS | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 | $6.49 | $9.64 |
| % Growth | - | -29.2% | 62.2% | 38.1% | 206.9% | 178.6% | 48.5% |
| Operating Cash Flow | -$641.7 | -$541.3 | $104.2 | -$8.3 | $524.1 | - | - |
| CapEx | $76.4 | $72.1 | $62.2 | $34.3 | $58.7 | - | - |
| Free Cash Flow | -$718.1 | -$613.3 | $41.9 | -$42.6 | $465.4 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $844.3 | $1,037.4 | $1,828.3 | $2,248.2 | $3,713.9 | $5,467.5 | $6,912.2 |
| Gross Profit | $729.3 | $897.2 | $1,560.1 | $1,941.7 | $3,036.8 | - | - |
| EBITDA | -$671.9 | -$746 | -$230.6 | -$121.8 | $556.4 | - | - |
| Net Income | -$852.8 | -$1,131.2 | -$440.2 | -$278.2 | $313.7 | - | - |
| Diluted EPS | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 | $6.49 | $9.64 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $820 | $866.4 | $812.7 | $966.4 | $1,657.2 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | $647.2 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$641.7 | -$541.3 | $104.2 | -$8.3 | $524.1 |
| Capital Expenditure | $76.4 | $72.1 | $62.2 | $34.3 | $58.7 |
| Free Cash Flow | -$718.1 | -$613.3 | $41.9 | -$42.6 | $465.4 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% |
| Gross Margin | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| EBITDA Margin | -79.6% | -71.9% | -12.6% | -5.4% | 15.0% |
| Net Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| FCF Margin | -85.0% | -59.1% | 2.3% | -1.9% | 12.5% |
| Diluted EPS Growth | - | -29.2% | 62.2% | 38.1% | 206.9% |
Get the ALNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.